title: MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.
authors.affiliation: Umea, Sweden.
authors.forename: Anders
authors.initials: A
authors.lastname: Svenningsson
authors.affiliation: Umea, Sweden.
authors.forename: Peter
authors.initials: P
authors.lastname: Sundstrom
authors.affiliation: Umea, Sweden.
authors.forename: Jonatan
authors.initials: J
authors.lastname: Salzer
authors.affiliation: Umea, Sweden.
authors.forename: Mattias
authors.initials: M
authors.lastname: Vagberg
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors